When the PI3K/Akt/mTOR pathway was inhibited, a more prominent decrease in cardiac hypertrophy, NF-κB, and IκBb was noted, providing evidence that TLR4 downstream metabolites can be affected by different TLR pathways which could be contributing to cardiac hypertrophy. The gene discussed is TLR4; the disease is cardiac hypertrophy.